Published in Am J Pathol on April 09, 2013
Bevacizumab Against Recurrent Retinal Detachment (BEARRD) | NCT02192970
Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid. Mediators Inflamm (2013) 1.11
A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor α. Mol Cell Biol (2013) 0.84
RasGAP Promotes Autophagy and Thereby Suppresses Platelet-Derived Growth Factor Receptor-Mediated Signaling Events, Cellular Responses, and Pathology. Mol Cell Biol (2015) 0.81
Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy. Am J Pathol (2014) 0.80
Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients. Graefes Arch Clin Exp Ophthalmol (2014) 0.77
Expression of VEGF-A, Otx homeobox and p53 family genes in proliferative vitreoretinopathy. Mediators Inflamm (2013) 0.77
Intravitreal Injection of Bevacizumab in Primary Vitrectomy to Decrease the Rate of Retinal Redetachment: A Randomized Pilot Study. J Ophthalmic Vis Res (2016) 0.75
Vascular Endothelial Cell Growth Factor A Acts via Platelet-Derived Growth Factor Receptor α To Promote Viability of Cells Enduring Hypoxia. Mol Cell Biol (2016) 0.75
Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels. Clin Ophthalmol (2016) 0.75
Proliferative vitreoretinopathy and antivascular endothelial growth factor treatment. Eye (Lond) (2014) 0.75
Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells. Clin Ophthalmol (2016) 0.75
Suppressive effect of AMP-activated protein kinase on the epithelial-mesenchymal transition in retinal pigment epithelial cells. PLoS One (2017) 0.75
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology (2006) 9.01
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem (1994) 6.18
Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta (2010) 4.99
Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Arch Ophthalmol (1997) 2.42
Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul (1990) 2.31
Proliferative vitreoretinopathy: an overview. Surv Ophthalmol (1998) 1.74
Chemokines in health and disease. Exp Cell Res (2011) 1.69
Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol (1996) 1.68
Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol (1997) 1.58
Second AKT: the rise of SGK in cancer signalling. Growth Factors (2010) 1.57
Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res (1995) 1.49
Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (1999) 1.49
Differences in the regulation of fibroblast contraction of floating versus stressed collagen matrices. J Biol Chem (1999) 1.49
The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog Retin Eye Res (2005) 1.47
Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br J Ophthalmol (2004) 1.43
A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (2007) 1.41
Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) (2002) 1.39
Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol (2008) 1.38
Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci (2007) 1.38
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology (2006) 1.37
In vivo models of proliferative vitreoretinopathy. Nat Protoc (2007) 1.36
Purification of human platelet-derived growth factor. Methods Enzymol (1985) 1.36
Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci (1994) 1.34
Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem (2009) 1.31
Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye (Lond) (2006) 1.30
Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology (1987) 1.29
Platelet-derived growth factor and its role in health and disease. Philos Trans R Soc Lond B Biol Sci (1990) 1.27
Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res (1993) 1.20
Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci (1999) 1.20
Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res (2009) 1.19
Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem (1999) 1.14
Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm (2006) 1.13
N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol (2010) 1.11
Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest Ophthalmol Vis Sci (2000) 1.11
Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med (2011) 1.10
An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci (2002) 1.06
PDGF receptors are activated in human epiretinal membranes. Exp Eye Res (2008) 1.06
Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53. Mol Cell Biol (2011) 1.06
A comparison of different cellular inocula in an experimental model of massive periretinal proliferation. Am J Ophthalmol (1982) 1.01
Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol (2001) 1.00
A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am J Pathol (2011) 0.99
Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci (2009) 0.99
Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol (2003) 0.97
Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (1995) 0.96
Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Ophthalmic Res (2007) 0.96
Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol Cell Biol (2012) 0.95
Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy. Retina (2004) 0.94
Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am J Ophthalmol (2002) 0.93
Growth factors in proliferative vitreoretinopathy. Br J Ophthalmol (1998) 0.93
Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy. Ophthalmic Res (2011) 0.93
Proliferative vitreoretinopathy: developments in pathogenesis and treatment. Compr Ophthalmol Update (2006) 0.92
Intravitreous fibronectin and platelet-derived growth factor. New model for traction retinal detachment. Arch Ophthalmol (1986) 0.90
Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells. Can J Ophthalmol (2002) 0.90
Vitreous leptin levels in retinal disease. Eye (Lond) (2005) 0.90
Mechanisms in proliferative vitreoretinopathy. Ophthalmol Clin North Am (2002) 0.88
A novel function of p53: a gatekeeper of retinal detachment. Am J Pathol (2012) 0.87
Cholesterol, cytokines and diseases. Int J Immunopathol Pharmacol (2011) 0.81
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet (2008) 7.07
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology (2011) 6.33
Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med (2006) 4.46
Oral fluoroquinolones and the risk of retinal detachment. JAMA (2012) 4.43
Structure prediction for CASP8 with all-atom refinement using Rosetta. Proteins (2009) 3.64
The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol (2006) 3.60
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science (2011) 3.49
Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford) (2009) 3.33
Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology (2010) 3.22
Clinical outcomes after lumbar discectomy for sciatica: the effects of fragment type and anular competence. J Bone Joint Surg Am (2003) 3.14
Schistosoma haematobium infection in workers returning from Africa to China. J Travel Med (2013) 3.14
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol (2009) 2.95
Simple, inexpensive technique for high-quality smartphone fundus photography in human and animal eyes. J Ophthalmol (2013) 2.60
PDGF signaling in cells and mice. Cytokine Growth Factor Rev (2004) 2.57
Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology (2011) 2.47
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol (2006) 2.45
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
Teleophthalmology screening for diabetic retinopathy through mobile imaging units within Canada. Can J Ophthalmol (2008) 2.30
Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci (2009) 2.17
Closed globe macular injuries after blasts in combat. Retina (2013) 2.09
Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. Am Heart J (2002) 2.04
Optical colonoscopy and virtual colonoscopy numbers after initiation of a CT colonography program: long term data. J Gastrointestin Liver Dis (2012) 2.00
High-resolution comparative modeling with RosettaCM. Structure (2013) 1.96
Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo. Circ Res (2004) 1.93
Activations in visual and attention-related areas predict and correlate with the degree of perceptual learning. J Neurosci (2007) 1.74
Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci (2010) 1.73
Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci (2008) 1.70
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One (2008) 1.68
Maternal influence on blood pressure suggests involvement of mitochondrial DNA in the pathogenesis of hypertension: the Framingham Heart Study. J Hypertens (2007) 1.67
Use of topiramate and risk of glaucoma: a case-control study. Am J Ophthalmol (2012) 1.66
miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev (2011) 1.66
Attenuated expression of profilin-1 confers protection from atherosclerosis in the LDL receptor null mouse. Circ Res (2007) 1.64
Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res (2013) 1.61
Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther (2011) 1.55
Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann Rheum Dis (2010) 1.53
Vertical ridge augmentation by means of deproteinized bovine bone block and recombinant human platelet-derived growth factor-BB: a histologic study in a dog model. Int J Periodontics Restorative Dent (2006) 1.53
The G12 family of G proteins as a reporter of thromboxane A2 receptor activity. Mol Pharmacol (2006) 1.53
A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat Cell Biol (2003) 1.53
Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) (2010) 1.53
Case records of the Massachusetts General Hospital. Case 5-2006. An 11-year-old girl with loss of vision in the right eye. N Engl J Med (2006) 1.51
Power and type I error rate of false discovery rate approaches in genome-wide association studies. BMC Genet (2005) 1.50
Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem (2012) 1.50
Platelet-derived growth factor receptor-mediated signal transduction from endosomes. J Biol Chem (2003) 1.49
Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res (2007) 1.49
Decreased optical coherence tomography-measured pericentral retinal thickness in patients with diabetes mellitus type 1 with minimal diabetic retinopathy. Br J Ophthalmol (2007) 1.48
Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO J (2007) 1.46
Smartphone photography safety. Ophthalmology (2012) 1.44
Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls. Arthritis Rheum (2013) 1.43
A randomized controlled trial of an internal family systems-based psychotherapeutic intervention on outcomes in rheumatoid arthritis: a proof-of-concept study. J Rheumatol (2013) 1.43
A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci (2007) 1.41
Isolated vitreoretinal amyloidosis in the absence of transthyretin mutations. Arch Ophthalmol (2004) 1.40
Assessment of predictions submitted for the CASP7 domain prediction category. Proteins (2007) 1.39
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol (2003) 1.39
Visual outcomes of vitreoretinal surgery in eyes with severe open-globe injury presenting with no-light-perception vision. Graefes Arch Clin Exp Ophthalmol (2009) 1.39
Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J (2012) 1.38
Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell (2005) 1.35
Infections following arthroscopic anterior cruciate ligament reconstruction. Arthroscopy (2006) 1.34
The correlation between height of macular detachment and visual outcome in macula-off retinal detachments of < or = 7 days' duration. Ophthalmology (2005) 1.33
Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol (2006) 1.33
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol (2012) 1.33
Predictors of visual outcome and choroidal neovascular membrane formation after traumatic choroidal rupture. Arch Ophthalmol (2006) 1.32
Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci (2012) 1.32
Perforating globe injuries during operation Iraqi Freedom. Ophthalmology (2008) 1.31
Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem (2009) 1.31
A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration. J Cell Sci (2004) 1.30
IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther (2007) 1.30
Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell (2004) 1.28
Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci (2002) 1.26
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum (2010) 1.25
Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis (2013) 1.25
Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol (2008) 1.23
Toll-like receptor 4-dependent activation of dendritic cells by a retrovirus. J Virol (2004) 1.23
Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther (2012) 1.22
Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia. Arterioscler Thromb Vasc Biol (2007) 1.22
Pericytes and ocular diseases. Exp Eye Res (2007) 1.21
Structural genomics of pathogenic protozoa: an overview. Methods Mol Biol (2008) 1.20
Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res (2009) 1.19
MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. J Immunol (2004) 1.19
Characterization of mammographic masses based on level set segmentation with new image features and patient information. Med Phys (2008) 1.18
Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J Biol Chem (2007) 1.18
Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol (2006) 1.18
Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension (2005) 1.17
Sensitivity and optimization of artificial digestion in the inspection of meat for Trichinella spiralis. Foodborne Pathog Dis (2010) 1.17
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest (2011) 1.16
Complement-associated deposits in the human retina. Invest Ophthalmol Vis Sci (2008) 1.15
Effect of age on individual retinal layer thickness in normal eyes as measured with spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci (2013) 1.15
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol (2002) 1.14
Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem (2002) 1.14
Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol (2004) 1.14
Kidneys in hypertensive rats show reduced response to nitric oxide synthase inhibition as evaluated by BOLD MRI. J Magn Reson Imaging (2003) 1.13
Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human bronchial epithelial cells. J Biol Chem (2003) 1.12
IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B (2006) 1.12
N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol (2010) 1.11